2019 Packaging Pharmaceutical Companies 
European Pharmaceutical Review
AUGUST 23, 2022
On- or in-dose authentication means that a security measure or anticounterfeit feature is integrated with the dosage form itself, offering product verification and traceability embedded into each medicine, rather than on the secondary package” WHO estimates that >50 percent of the drugs for sale on the internet are fake. References.
European Pharmaceutical Review
APRIL 21, 2023
The ERA therefore needs teeth – which does not mean it should be a barrier to the authorisation of new medicines – but it should require pharmaceutical companies to minimise harmful effects on the environment, which indirectly also harm our health. cited 23Apr]. Available from: [link]. Steenmeijer M, et al. Lancet Planetary Health.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
APRIL 11, 2022
From patients, patient bodies, pharmaceutical companies, and academia, to regulatory bodies, public institutions, and small and medium-sized enterprises (SMEs), all key stakeholders must come together to help the patients who most need new medicines to access them as quickly as possible. About the author.
Pharmaceutical Technology
JUNE 19, 2023
Pharmaceutical companies are putting their trust in the immense potential this new generation of medicine has for treating individuals with rare genetic diseases, which currently affect an estimated 280 million patients worldwide. Products are stored and packaged in a dedicated suite by a dedicated team,” explains MacNeir.
ISPE
MARCH 7, 2023
As such there’s a growing question of how the industry will improve the sustainability profile of its existing medicines and ensure that sustainability is designed into new medicines, such as products, with a reduced environmental risk, greener manufacturing technologies, and recyclable delivery systems and packaging. 9 December 2021.
pharmaphorum
AUGUST 16, 2021
In 2019, Formedix collaborated with a UK-based consortium interested in observing early safety data. These are now used by several regulatory bodies, including the Food and Drug Administration (FDA) and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for submission packages. About the interviewee.
pharmaphorum
NOVEMBER 29, 2021
iii] It’s no longer just about the company, compensation package and secondary benefits (e.g., Mark Larsen is vice president and head of human resources for Europe, Middle East and Africa (EMEA) at Janssen, the Pharmaceutical Companies of Johnson & Johnson. gym membership).
Expert insights. Personalized for you.
98 
Let's personalize your content